Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the most effective treatments for prostate cancers that have spread to other organs (metastasized). The benefits of hormone treatments do not last, however. Over time, many prostate cancers continue to grow despite hormonal therapies; these are called “castration-resistant prostate cancers.”
The purpose of this study is to find the highest dose of an investigational drug called CC-115 that can be given safely in men with castration-resistant prostate cancer, and to assess its preliminary effectiveness against this cancer. CC-115 works by blocking the activity of two proteins that fuel cancer growth: “mTOR” and “DNA-dependent protein kinase.” CC-115 is taken orally (by mouth).